Related Experiment Video

Updated: Aug 14, 2026

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2

Tatsuo Kanda1, Osamu Yokosuka, Fumio Imazeki

  • 1Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Japan. kandat-cib@umin.ac.jp

DNA and Cell Biology
|December 8, 2005
PubMed

Insights

This study shows that combining Bcl-2 small interfering RNA (siRNA) with 5-fluorouracil (5-FU) significantly enhances apoptosis in human hepatocellular carcinoma (HCC) cell lines, offering a potential new therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Hepatocellular carcinoma (HCC) is a significant global health concern.
  • 5-fluorouracil (5-FU) is a common chemotherapeutic agent for HCC, but its efficacy can be limited.
  • Bcl-2 is an anti-apoptotic protein that can confer resistance to cancer therapy.

Purpose of the Study:

  • To investigate whether Bcl-2 small interfering RNA (siRNA) can enhance 5-FU-induced apoptosis in human HCC cell lines.
  • To evaluate the combined therapeutic potential of Bcl-2 siRNA and 5-FU for HCC treatment.

Main Methods:

  • Human HCC cell lines were treated with or without 5-FU.
  • Cells were transfected with Bcl-2 siRNA or control siRNA.
  • Bcl-2 protein expression was assessed by Western blotting.
  • Cell viability was measured using MTS assay.
  • Apoptosis occurrence was evaluated using an apoptosis assay.

Main Results:

  • Transfection with Bcl-2 siRNA significantly reduced Bcl-2 protein expression compared to controls.
  • Combined treatment with Bcl-2 siRNA and 5-FU significantly reduced cell viability in all tested HCC cell lines.
  • Pre-treatment with Bcl-2 siRNA followed by 5-FU treatment resulted in the highest proportion of apoptosis (19.5%) compared to other groups.

Conclusions:

  • Bcl-2 siRNA effectively suppresses Bcl-2 expression in HCC cells.
  • The combination of Bcl-2 siRNA and 5-FU demonstrates enhanced efficacy in reducing HCC cell viability and inducing apoptosis.
  • This combination therapy presents a promising novel therapeutic strategy for hepatocellular carcinoma.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...